MOBIUS SCIENTIFIC INC.

Biotech · Private

Lipoprotein nanoparticle (nanodisc) therapeutics for cholesterol removal from the eye to treat age-related macular degeneration

Grants
$277K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
6
0 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Cholesterol Removal as a Treatment for Dry Age-Related Macular Degeneration$276,758
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2222Tmunity Therapeutics—$140M
2223Alloy Therapeutics—$147M
2224ArriVent Biopharma—$191M
2225MOBIUS SCIENTIFIC INC.——
2226PMV Pharmaceuticals—$74M
2227FibroBiologics, LLC—$11M
2228Diagonal Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 6
  • Particle Compositions And Uses Thereofapplication
  • Methods For Treating Lipid-related Eye Diseasesapplication
  • Particle Compositions And Uses Thereofapplication
  • Methods For Treating Lipid-related Eye Diseasesapplication
  • Particle Compositions And Uses Thereofapplication
  • Nanodiscs For Use In Removing Lipid Accumulation In The Eyeapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.